Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Nucana ( (NCNA) ) has issued an update.
On June 27, 2025, NuCana plc entered into a Sales Agreement with A.G.P./Alliance Global Partners and Laidlaw & Company (UK) Ltd., allowing the company to offer and sell American Depositary Shares (ADSs) up to an aggregate amount of $100 million. This move, facilitated through a shelf registration statement, aims to provide NuCana with financial flexibility to support its operations and strategic initiatives. Additionally, on the same date, NuCana held its Annual General Meeting in Edinburgh, where all proposed resolutions were passed, indicating strong shareholder support.
The most recent analyst rating on (NCNA) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on Nucana stock, see the NCNA Stock Forecast page.
Spark’s Take on NCNA Stock
According to Spark, TipRanks’ AI Analyst, NCNA is a Underperform.
Nucana’s overall score is primarily impacted by its financial instability and negative valuation metrics. The significant lack of revenue generation and operational losses are major concerns. Despite showing strong cash management and low leverage, the company’s technical indicators suggest a bearish trend, further weighing down the score. The poor valuation metrics, such as a negative P/E ratio, are offset by potential speculative interest due to the low stock price. The absence of notable earnings call insights or corporate events means these factors did not influence the score.
To see Spark’s full report on NCNA stock, click here.
More about Nucana
NuCana plc is a biotechnology company based in the United Kingdom, focused on developing novel cancer treatments. The company specializes in transforming chemotherapy agents into more effective and safer medicines using its proprietary ProTide technology.
Average Trading Volume: 144,543,380
Technical Sentiment Signal: Sell
Current Market Cap: $520.3K
For a thorough assessment of NCNA stock, go to TipRanks’ Stock Analysis page.